Profiel
David L.
Corbet has been President, Chief Operating Officer and a Director of Matritech, Inc. since October 1993.
He joined Matritech as Executive Vice President in April 1993.
Prior to joining Matritech, Mr. Corbet was President and Chief Operating Officer of T Cell Diagnostics, Inc. from 1991 to April 1993.
Eerdere bekende functies van David L. Corbet
| Bedrijven | Functie | Einde |
|---|---|---|
MZT Holdings, Inc.
 MZT Holdings, Inc. Medical SpecialtiesHealth Technology MZT Holdings, Inc. principal activity is to develop, manufacture, market, distribute and licensing of cancer diagnostic technologies and products. The products are based on proprietary nuclear matrix protein technology. The company has developed minimally invasive cancer diagnostic tests for bladder and colon cancer, cervical cancer, breast cancer and prostrate cancer, using proprietary technology and expertise. It was founded in 1987 and is headquartered Foxborough, MA. | Directeur/Bestuurslid | 20-06-2012 |
Matritech, Inc.
 Matritech, Inc. Medical SpecialtiesHealth Technology Matritech, Inc. is a biotechnology company principally engaged in the development, manufacture, marketing, distribution and licensing of cancer diagnostic technologies, products and services | President | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Matritech, Inc.
Matritech, Inc. Medical SpecialtiesHealth Technology Matritech, Inc. is a biotechnology company principally engaged in the development, manufacture, marketing, distribution and licensing of cancer diagnostic technologies, products and services | Health Technology |
MZT Holdings, Inc.
MZT Holdings, Inc. Medical SpecialtiesHealth Technology MZT Holdings, Inc. principal activity is to develop, manufacture, market, distribute and licensing of cancer diagnostic technologies and products. The products are based on proprietary nuclear matrix protein technology. The company has developed minimally invasive cancer diagnostic tests for bladder and colon cancer, cervical cancer, breast cancer and prostrate cancer, using proprietary technology and expertise. It was founded in 1987 and is headquartered Foxborough, MA. | Health Technology |